Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.

Prahalada S, Block G, Handt L, DeBurlet G, Cahill M, Hoe CM, van Zwieten MJ

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1 Feb 1999Cited by 9 (Europe PMC)

PMID10226793DOI10.1055/s-2007-978710PepBankPUB-10226793

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In normal dogs, MK-0677 administration significantly increased body weight gain.
In plain wordsIn dogs, MK-0677 significantly increased body weight gain.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseBody weight gain
Study
Dogn = 4
Normal young adult male dogs
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg/kg/day · oral · 15 daysAs given in this study (Dog).
Source sentences
Summary
Administration of MK-0677 or pGH resulted in a statistically significant (P < or = 0.05) increased body weight gain and increased serum IGF-1 and GH levels.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
Report a problemFND-1022679301
02AnimalAnimal study (in vivo)Efficacy outcome
In normal dogs, MK-0677 administration significantly increased serum IGF-1.
In plain wordsIn dogs, MK-0677 significantly increased serum IGF-1.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseSerum IGF-1
Study
Dogn = 4
Normal young adult male dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5 mg/kg/day · oral · 15 daysAs given in this study (Dog).
Source sentences
Summary
Administration of MK-0677 or pGH resulted in a statistically significant (P < or = 0.05) increased body weight gain and increased serum IGF-1 and GH levels.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
Report a problemFND-1022679302
03AnimalAnimal study (in vivo)Efficacy outcome
In normal dogs, MK-0677 administration significantly increased serum GH.
In plain wordsIn dogs, MK-0677 significantly increased serum growth hormone.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseSerum GH
Study
Dogn = 4
Normal young adult male dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5 mg/kg/day · oral · 15 daysAs given in this study (Dog).
Source sentences
Summary
Administration of MK-0677 or pGH resulted in a statistically significant (P < or = 0.05) increased body weight gain and increased serum IGF-1 and GH levels.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
Report a problemFND-1022679303
04AnimalAnimal study (in vivo)Efficacy outcome
In normal dogs, MK-0677 did not significantly increase CSF IGF-1 on days 7 or 15.
In plain wordsIn dogs, MK-0677 did not significantly increase cerebrospinal fluid IGF-1.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCSF IGF-1
Study
Dogn = 4
Normal young adult male dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5 mg/kg/day · oral · 15 daysAs given in this study (Dog).
Source sentences
Summary
In contrast, administration of MK-0677 resulted in no significant (P > 0.05) increase in CSF IGF-1 or GH levels on days 7 or 15 of the study.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
Report a problemFND-1022679304
05AnimalAnimal study (in vivo)Efficacy outcome
In normal dogs, MK-0677 did not significantly increase CSF GH on days 7 or 15.
In plain wordsIn dogs, MK-0677 did not significantly increase cerebrospinal fluid growth hormone.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCSF GH
Study
Dogn = 4
Normal young adult male dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5 mg/kg/day · oral · 15 daysAs given in this study (Dog).
Source sentences
Summary
In contrast, administration of MK-0677 resulted in no significant (P > 0.05) increase in CSF IGF-1 or GH levels on days 7 or 15 of the study.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
Report a problemFND-1022679305

Studies that did not test the peptide alone2

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

06AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Efficacy outcome
In normal dogs, CSF IGF-1 ranged from 1.2 to 2.0 ng/ml across samples, including those after MK-0677.
In plain wordsIn dogs, cerebrospinal fluid IGF-1 varied little across samples, including those after MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableCSF IGF-1 concentration range
Study
Dogn = 12
Normal young adult male dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
CSF IGF-1
1.2 to 2 ng/ml
all groups
Source sentences
Summary
The CSF IGF-1 values ranged from 1.2 to 2.0 ng/ml with minimal variation among three separate samples taken during the course of the study from each dog.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-1022679306
07AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Efficacy outcome
In normal dogs, CSF GH remained very low irrespective of treatment group, including MK-0677.
In plain wordsIn dogs, cerebrospinal fluid growth hormone remained very low in all groups, including MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableCSF GH concentration range
Study
Dogn = 12
Normal young adult male dogs
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Similarly, the CSF GH levels were very low (< 0.98 ng/ml to 2.4 ng/ml) in all dogs irrespective of treatment group.
3 context sentences(design, population, supporting numbers)
Summary · context
A total of 12 normal, young adult male dogs were randomized to three treatment groups (4 dogs/group) based on body weight.
Summary · context
A group of 4 dogs were dosed orally with MK-0677 (5 mg/kg/day) dissolved in deionized water.
Summary · context
From all dogs, blood and CSF samples were collected prior to the initiation of treatment and on days 7 and 15 of treatment.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-1022679307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.